Department of Pharmacology of Biomedical Drugs

The activities of the Department of Pharmacology of Biomedical Drugs are aimed at conducting experimental (biomedical) and preclinical studies of medicinal products (MPs), immunobiological preparations (IBPs), radiopharmaceutical preparations (RPhPs), biomedical cell products (BMCPs), gene therapy preparations (GTPs), as well as developing and implementing methodological recommendations for the preclinical study of innovative medicinal products in accordance with national and international protocols:

• developing new approaches, methods and recommendations for the diagnosis, treatment and improvement of the quality of life of patients with malignant neoplasms within the framework of translational medicine • experimental (biomedical) and preclinical study of the pharmacodynamics of MPs, IBPs, RPhPs, BMCPs and GTPs in in vitro and in vivo test systems • development and characterization of relevant in vitro and in vivo test systems for the study of targeted MPs, IBPs, RPhPs, BMCPs and GTPs • study of the effects of MPs, RPhPs and GTPs on metastasis processes • study of the radio- and chemomodifying properties of medicinal products • development of indications and criteria for evaluating the efficacy of medicinal products that are modifiers of the therapeutic efficacy of radiotherapy and chemotherapy • assessment of the therapeutic pathomorphosis in animals • study of the mechanism of action of antitumor MPs, IBPs and GTPs • preclinical study of the general toxic properties and specific types of toxicity of MPs, IBPs, RPhPs, GTPs and BMCPs in accordance with national and international protocols • study of the pharmacological safety of MPs, IBPs, RPhPs, GTPs and BMCPs • study of the mechanisms of toxic action of MPs, IBPs and GTPs • study of the pharmacokinetics and biodistribution of MPs, IBPs, RPhPs, GTPs and BMCPs • quality control of medicinal products in terms of physicochemical and biological quality indicators

The Department uses a wide range of modern methods designed for research in various areas:

• experimental oncology (in vitro and in vivo) • experimental pharmacology (in vitro and in vivo) • experimental toxicology (in vitro and in vivo)

Methods:

• hematology and coagulometry in experimental animals and humans • analytical biochemistry • preparative and analytical immunochemistry • cellular immunology • enzyme immunoassay • flow cytometry • histology of internal organs of experimental animals • immunocytochemistry and immunohistochemistry for the detection of specific antigens in cells of normal and tumor tissues of animals and humans

Medicinal products that underwent preclinical trials at the A. Tsyb MNIOI named after P.A. Herzen — a branch of the FSBI “NMIC of Radiology” of the Ministry of Health of Russia in 2005–2026:

1. Antitumor therapy (synthetic cytostatic drugs)

• Doxorubicin-NF (Phase I clinical trials are being initiated)

2. Antitumor therapy (biomedical preparations)

• EnteroMix (Phase I clinical trials are ongoing)
• A medicinal product based on oncolytic Ad6 with an embedded GM-CSF gene and an hTERT gene promoter, carrying a chimeric fiber protein — (Ad6/3-hTERT-GM-CSF)

3. Fluorescence diagnostics and photodynamic therapy

• Photesan (registered, R N000199/02, 2013-09-18)
• Alasense (registered, LP-001848, 2018-12-12)
• Alasense gel (preclinical studies completed)
• Gexasense (Phase I clinical trials completed)
• Holosense lyo (preclinical studies completed)
• Holosense gel (preclinical studies completed)
• Chlorin e liposomal (preclinical studies completed)
• Natural bacteriochlorin (λ = 800 nm; preclinical studies completed)
• Synthetic bacteriochlorin (λ = 747 nm; preclinical studies completed)
• Synthetic derivative of O-propyloxime-N-propoxybacteriopurpurinimide (BPI) (λ = 810 nm; preclinical studies completed)

4. Binary catalytic therapy

• Theraftal (Phase II clinical trials completed)
• Oxycobalamin (Phase II clinical trials ongoing)
• Efiter (clinical trials completed)

5. Hyperthermia

• Nanosense (preclinical studies completed)

6. Targeted therapy

• Imutеран (Phase I clinical trials completed)
• Manselan (preclinical studies completed)

7. Radionuclide targeted therapy

• MNT with Auger electron emitters (preclinical studies ongoing)
• RPhPs with beta-emitting radioisotopes lutetium-177 and lead-212
• An RPhP based on samarium-153 in a thermosensitive carrier for local radiation therapy of tumors (preclinical studies completed)

8. Gene antitumor therapy

• Elenagen (Phase II clinical trials)
• AntioncoRAN-M (Phase I clinical trials completed; approval obtained, Phase II clinical trials ongoing)
• AntioncoRAN-F (preclinical studies)
• GenTerPlus (experimental studies)

9. Anti-inflammatory, antioxidant therapy

• Lantox (preclinical studies)
• Laprot (registered, LS-002374, 2015-05-20)
• Lactoftal (Phase II clinical trials)
• AdeLact (Phase I clinical trials)

10. Metabolic, supportive therapy

• Deltaran (registered, LP-003849, 2016-09-20)
• Remaxol (registered, LSR-009341/09, 2020-02-13)
• Runikhol (preclinical studies)

11. Immunomodulating therapy

• GMDP-A (preclinical studies completed)
• HLDF6 peptide (preclinical studies completed)
• Immunofan (registered, R N000106/02)

12. Antiviral therapy

• AdeVac-Flu (Phase I clinical trials)
• Dinavir (preclinical studies)
• Panavir (registered, R N000299/02, 2018-11-19)
• GamEvac, a vector-based vaccine against Ebola fever (registered, LP-003389, 2015-12-28)
• GamEvac-Combi, a combined vector vaccine against Ebola fever (registered, LP-003390, 2018-05-14)
• Antirabitel (Phase I clinical trials)
• CombiMab (preclinical studies completed)
• CombiMab-2 (preclinical studies completed)
• Dengue virus vaccine (preclinical studies completed)

13. Therapy of orphan diseases

• AdeVask (Phase I clinical trials)

14. Radio- and chemo-modifying medicinal products, implantable materials

• Heparinized iron oxide nanoparticles (preclinical studies completed)
• SferoGEL (study of the effect on tumor growth)

15. Diagnostic medicinal products

Arguscan (preclinical studies completed)

Lymphotropin (preclinical studies)

BioNAF (preclinical studies completed)

1. Regulatory Framework

• Federal Law No. 61-FZ “On the Circulation of Medicinal Products” dated April 12, 2010 (as amended)
• GOST 33044-2014 “Principles of Good Laboratory Practice”
• Decision of the Council of the Eurasian Economic Commission No. 78 dated November 3, 2016 “On the Rules of Registration and Expertise of Medicinal Products for Medical Use”
• Decision of the Council of the Eurasian Economic Commission No. 81 dated November 3, 2016 “On Approval of the Good Laboratory Practice Rules of the Eurasian Economic Union in the Sphere of Medicinal Products Circulation”

2. National Methodological Framework for Preclinical Studies of Medicinal Products

Methodological guidelines and protocols used by the Department in conducting preclinical studies of medicinal products:

• Guidelines for Experimental (Preclinical) Study of New Pharmacological Substances / Ed. by R.U. Khabriev — Moscow, 2005
• Guidelines for Preclinical Studies of Medicinal Products. Part One / Ed. by A.N. Mironov — Moscow: Grif i K, 2012
• Guidelines for Preclinical Studies of Medicinal Products (Immunobiological Medicinal Preparations). Part Two / Ed. by A.N. Mironov — Moscow: Grif i K, 2012
  1. Study of the toxicity of medicinal products after a single administration (acute toxicity)
  2. Study of the toxicity of medicinal products after repeated administration (subchronic / chronic toxicity)
  3. Assessment of the cumulative properties of medicinal products
  4. Study of the immunotoxic properties of medicinal products
  5. Study of the allergenic properties of medicinal products
  6. Study of the reproductive toxic properties of medicinal products
  7. Study of the carcinogenic properties of medicinal products
  8. Assessment of the local tolerability of medicinal products

3. International Methodological Framework for Preclinical Studies of Medicinal Products

3.1 Organisation for Economic Co-operation and Development (OECD), OECD Guidelines for the Testing of Chemicals, Section 4, used by the Department in conducting preclinical studies of medicinal products:

• OECD Test Guideline No. 402 “Acute Dermal Toxicity” (GOST 32373-2013)
• OECD Test Guideline No. 404 “Acute Dermal Irritation / Corrosion” (GOST 32436-2013)
• OECD Test Guideline No. 406 “Skin Sensitisation” (GOST 32375-2013)
• OECD Test Guideline No. 407 “Repeated Dose 28-Day Oral Toxicity Study in Rodents” (GOST 32641-2014)
• OECD Test Guideline No. 408 “Repeated Dose 90-Day Oral Toxicity Study in Rodents” (GOST 32637-2014)
• OECD Test Guideline No. 410 “Repeated Dose 28/21-Day Dermal Toxicity Study” (GOST 32642-2014)
• OECD Test Guideline No. 411 “Subchronic Dermal Toxicity: 90-Day Study” (GOST 32639-2014)
• OECD Test Guideline No. 420 “Acute Oral Toxicity — Fixed Dose Procedure” (GOST 32296-2013)
• OECD Test Guideline No. 423 “Acute Toxic Class Method” (GOST 32644-2014)
• OECD Test Guideline No. 424 “Neurotoxicity Study in Rodents” (GOST 32645-2014)
• OECD Test Guideline No. 452 “Chronic Toxicity Studies” (oral administration) (GOST 32519-2013)
• OECD Test Guideline No. 452 “Chronic Toxicity Studies” (dermal administration) (GOST 32437-2013)
• OECD Test Guideline No. 453 “Combined Chronic Toxicity / Carcinogenicity Study” (GOST 32647-2014)

3.2 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH):

Methodological guidelines and protocols used by the Department in conducting preclinical studies of medicinal products:

• S3A; S3B “Pharmacokinetics and Toxicokinetics in Drug Safety Evaluation” (GOST 56702-2015)
• S6(R1) “Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. General Recommendations” (GOST 56699-2015)
• S7A “Safety Pharmacology Studies for Human Pharmaceuticals” (GOST 56700-2015)
• M3(R2) “Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals” (GOST 56701-2015)
• S2 “Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use” (GOST 57130-2016)
• S1A; S1B “Carcinogenicity Studies of Medicinal Products and Excipients” (GOST 57146-2016)
• S9 “Nonclinical Evaluation for Anticancer Pharmaceuticals” (GOST 57147-2016)
• S8 “Immunotoxicity Studies for Human Pharmaceuticals”

3.3 Eurasian Economic Union (EAEU). Agreement “On Common Principles and Rules for the Circulation of Medicinal Products within the EAEU”

Methodological guidelines and protocols used by the Department in conducting preclinical studies of medicinal products:

• Decision of the Council of the Eurasian Economic Commission No. 78 dated November 3, 2016 “On the Rules of Registration and Expertise of Medicinal Products for Medical Use”
• Decision of the Council of the Eurasian Economic Commission No. 81 dated November 3, 2016 “On Approval of the Good Laboratory Practice Rules of the Eurasian Economic Union in the Sphere of Medicinal Products Circulation”
• Decision of the Council of the Eurasian Economic Commission No. 89 “On Approval of the Rules for Conducting Studies of Biological Medicinal Products of the Eurasian Economic Union”
• Decision of the Board of the Eurasian Economic Commission No. 202 dated November 26, 2019 “On Approval of the Guidelines for Nonclinical Safety Studies for the Conduct of Clinical Trials and Marketing Authorization of Medicinal Products”

The Department of Pharmacology of Biomedical Drugs maintains a unique experimental bank of human and animal tumors:

1. Human and animal cell lines of various histogenetic origins:

• Human tumor cell cultures of various locations — 56
• Mouse tumor cell cultures of various locations — 24
• Rat tumor cell cultures of various locations — 3
• Conditionally normal human cells — 4
• Conditionally normal monkey cells — 1

2. Sources of cell cultures:

• D.I. Ivanovsky Institute of Virology — branch of the FSBI “N.F. Gamaleya National Research Center for Epidemiology and Microbiology”
• ATCC
• Institute of Cytology of the Russian Academy of Sciences (RAS)
• CLS Cell Lines Service

3. Transplantable tumor strains of mice, rats and rabbits of various histogenetic origins:

• Mouse tumor strains of various origins — 31
• Rat tumor strains of various origins — 12
• Rabbit tumor strain — 1

4. Source of animal tumor strains:

• N.N. Blokhin National Medical Research Center of Oncology

1. Certified laboratory animals of MD (conventional) status are used in the studies:

• Interlinear mouse hybrids: CBA × C57/BL/6; C57/BL/6 × DBA/2
• Rats: CD; Wistar
• Guinea pigs: albinos; Agouti
• Rabbits: “Soviet Chinchilla” breed

Animals of SPF status:

• Mouse lines: CBA; DBA/2; BALB/c; C57Bl/6; ICR (CD-1)
• Immunodeficient mice: NU-A/A Tyrc/Tyrc Foxn1nu/Foxn1nu; NOD-Prkdcscid Il2rgem1/Smoc; NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzIcg
• Rats: Sprague Dawley; Wistar

2. All work with laboratory animals is carried out in accordance with national and international standards for the humane treatment of laboratory animals used in biomedical research:

• European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS No. 123)
• Council of Europe Directive 2010/63/EU “On the Protection of Animals Used for Scientific Purposes”
• GOST 33215-2014 “Rules of Equipping Premises and Organizing Procedures When Working with Laboratory Animals”
• GOST 33216-2014 “Rules for Working with Laboratory Rodents and Rabbits”

3. Certified suppliers of laboratory animals:

MD status:

• “Andreevka” Branch, Laboratory Animal Breeding Facility of the FSBSI “State Research Center of Biomedical Technologies” (SRCBT) of the Federal Medical and Biological Agency of Russia (FMBA)
• “Stolbovaya” Branch, Laboratory Animal Breeding Facility of the FSBSI SRCBT of the FMBA of Russia
• Krol Info LLC (Russia)

SPF status:

• Pushchino Nursery — branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (Russia)
• SPF Vivarium of the Institute of Cytology and Genetics (ICG) of the Siberian Branch of the RAS (Novosibirsk, Russia)
• Jackson Laboratory (USA)
• LBI LLC (China)

• Alekseenko IV, Snezhkov EV, Chernov IP, Pleshkan VV, Potapov VK, Sass AV, Monastyrskaya GS, Kopantzev EP, Vinogradova TV, Khramtsov YuV, Ulasov AV, Rosenkranz AA, Sobolev AS, Bezborodova OA, Plyutinskaya AD, Nemtsova ER, Yakubovskaya RI, Sverdlov ED. Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. Journal of Translational Medicine. 2015, 13(1), 78-89. DOI: 10.1186/s12967-015-0433-0
• Grammatikova NE, Vasilenko IA, Nemtsova ER, Yakubovskaya RI. Study of the antimicrobial activity spectrum in an in vitro experiment of preparations based on human lactoferrin Laprot® and the eye drop dosage form Laktoftal®. Drug Development & Registration. 2015; No. 1 (10), 152-157
• Yakubovskaya RI, Plyutinskaya AD, Lukyanets EA. Comparative study of photosensitizers of various classes in an in vitro system. Phthalocyanines. Russian Journal of Biotherapy, 2014, No. 4, 65-72
• Yakubovskaya RI, Plyutinskaya AD, Plotnikova EA, Grin MA, Mironov AF. Comparative study of photosensitizers of various classes in an in vitro system. Pyropheophorbides and chlorins. Russian Journal of Biotherapy — 2015. — No. 1. 43-51
• I. Alekseenko, E. Snezhkov, T. Vinogradova, G. Monastyrskaya, V. Potapov, V. Pleshkan, A. Sobolev, E. Nemtsova, R. Yakubovskaya, E. Sverdlov. Prospects for nonviral cancer gene therapy. Molecular Biology № 5 (49), 2015
• Gerasimova, G.K., Yakubovskaya, R.I., Pankratov, A.A., Nemtsova E.R., Andreeva T.N., Venediktova Yu.B., Plyutinskaya A.D., Bezborodova O.A., Sidorova T.A., Baryshnikov A.Yu., Kaliya O.L., Voroztsov, G.N., Luzhkov, Yu.M. Binary catalytic therapy: A new approach to treatment of malignant tumors. Results of pre-clinical and clinical studies. Russian Journal of General Chemistry, 2015, Vol. 85, No. 1, 289-302
• Yakubovskaya, R.I., Morozova, N.B., Pankratov, A.A., N. I. Kazachkina, A. D. Plyutinskaya, T. A. Karmakova, T. N. Andreeva, Yu. B. Venediktova, E. A. Plotnikova, E. R. Nemtsova, V. V. Sokolov, E. V. Filonenko, V. I. Chissov, B. Ya. Kogan, A. V. Butenin, Feofanov, A.V., Strakhovskaya, M.G. Experimental photodynamic therapy: 15 years of development. Russian Journal of General Chemistry, 2015, Vol. 85, No. 1, 217-239
• Pankratov AA, Andreeva TN, Yakubovskaya RI, Kaprin AD, Konarev AA, Yakunina TV, Lukyanets EA. A preparation for intraoperative visualization of “sentinel” lymph nodes. Russian Journal of Biotherapy. 2015; 14(4), 93-98.
• Plotnikova EA, Morozova NB, Plyutinskaya AD, Yakubovskaya RI, Chissov VI, Grin MA, Mironov AF. Specific activity of trimethyl ester of chlorin e6 and its glycosylated derivative in in vitro and in vivo systems. Russian Journal of Biotherapy, 2016; 25. 44-51
• Morozova NB, Plyutinskaya AD, Plotnikova EA, Yakubovskaya RI, Kaprin AD, Makarova EA, Dudkin SV, Lukyanets EA, Vorozhtsov GN. Evaluation of photophysical properties and photoinduced antitumor activity of cationic bromide salts of meso-tetra(N-alkyl-3-pyridyl) bacteriochlorin in in vitro and in vivo systems. Bulletin of the N.N. Blokhin Russian Cancer Research Center, 2015-2016; 26-27(4-1), 103-110
• Bezborodova OA, Nemtsova ER, Venediktova YuB, Alekseenko IV, Sobolev AS, Monastyrskaya GS, Yakubovskaya RI, Kaprin AD, Sverdlov ED. Experimental gene suicide antitumor therapy: development of an effective treatment regimen on a mouse sarcoma model. Biopharmaceutical Journal 2016; 8(2), 40-46
• Bezborodova OA, Nemtsova ER, Yakubovskaya RI, Kaprin AD. Gene therapy — a new direction in medicine. P.A. Herzen Journal of Oncology 2016; 5(2), 64-72
• Bezborodova OA, Nemtsova ER, Gevorkov AR, Boyko AV, Venediktova YuB, Alekseenko IV, Kostina MB, Monastyrskaya GS, Sverdlov ED, Khmelevsky EV, Yakubovskaya RI. Antitumor efficacy of combined gene and radiation therapy in animals. Doklady Biochemistry and Biophysics 2016; 470(4), 471-474
• Nemtsova ER, Bezborodova OA, Yakubovskaya RI, Kaprin AD. Gene therapy products in oncology: current state. Research and Practical Medicine. 2016, Vol. 3, No. 4, 33-43
• Slastnikova TA, Rosenkranz AA, Morozova NB, Vorontsova MS, Petriev VM, Lupanova TN, Ulasov AV, Zalutsky MR, Yakubovskaya RI, Sobolev AS. Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters. Int J Nanomedicine. 2017 Jan 10;12: 395-410. doi: 10.2147/IJN.S125359. eCollection 2017
• Vorontsova MS, Morozova NB, Karmakova TA, Rozenkrants AA, Slastnikova TA, Petriev VM, Smoryzanova OA, Tischenko VK, Yakubovskaya RI, Kaprin AD, Sobolev AS. Biodistribution of modular nanotransporter carrying Auger electron emitter and targeted to melanoma cells in murine tumor model. AIP Conference Proceedings. – 2017. -V.1882, 020078; [Электронный ресурс] Режим доступа doi: 
• Mironov AF, Grin MA, Pantushenko IV, Ostroverkhov PV, Ivanenkov YA, Filkov GI, Plotnikova EA, Karmakova TA, Starovoitova AV, Burmistrova NV, Yuzhakov VV, Romanko YS, Abakumov MA, Ignatova AA, Feofanov AV, Kaplan MA, Yakubovskaya RI, Tsigankov AA, Majouga AG. Synthesis and Investigation of Photophysical and Biological Properties of Novel S Containing Bacteriopurpurinimides. Journal of Medical Chemistry 2017, 60, 10220-10230
• Panchenko PA, Grin MA, Fedorova OA, Zakharko MA, Pritmov DA, Mironov AF, Arkhipova AN, Fedorov YV, Jonusauskas G, Yakubovskaya RI, Morozova NB, Ignatova AA, Feofanov AV. A novel bacteriochlorin-styrylnaphthalimide conjugate for simultaneous photodynamic therapy and fluorescence imaging. Physical Chemistry Chemical Physics. 2017 Nov 6. 19: 30195-30206. doi: 10.1039/c7cp04449f
• Vorontsova MS, Karmakova TA, Plotnikova EA, Morozova NB, Abakumov MA, Yakubovskaya RI, Alekseev BYa. Models of subcutaneous and orthotopic xenografts of human bladder cancer in nude mice for studying effects targeting the epidermal growth factor receptor. Russian Journal of Biotherapy. – 2018. – Vol. 17. – No. 2, 31-40
• Morozova NB, Plotnikova EA, Plyutinskaya AD, Stramova VO, Vorontsova MS, Pankratov AA, Yakubovskaya RI, Makarova EA, Lukyanets EA, Kaprin AD. Preclinical study of the preparation “Bacteriosense” intended for photodynamic therapy of malignant neoplasms, including prostate cancer. Russian Journal of Biotherapy. – 2018. – Vol. 17. – No. 3, 55-64
• Nemtsova ER, Bezborodova OA, Yakubovskaya RI, Kaprin AD. Principles and problems of suicide gene antitumor therapy. Molecular Medicine, 2018; 16 (6): 14-22. doi.org/10.29296/24999490-2018-06-03
• P.V. Ostroverkhov, A.S. Semkina, V.A. Naumenko, E.A. Plotnikova, P.A. Melnikov, T.O. Abakumova, R.I. Yakubovskaya, A.F. Mironov, S.S. Vodopyanov, A.M. Abakumov, A.G. Majouga, M.A. Grin, V.P. Chekhonin, M.A. Abakumov. Synthesis and characterization of bacteriochlorin loaded magnetic nanoparticles (MNP) for personalized MRI guided photosensitizers delivery to tumor. Journal of Colloid and Interface Science, 2018; 537: 132-141. doi.org/10.1016/j.jcis.2018.10.087
• E.A. Plotnikova, M.A. Grin, P.V. Ostroverkhov, I.V. Pantushenko, R.I. Yakubovskaya, A.D. Kaprin. Primary screening of photosensitizers of the bacteriochlorin series for photodynamic therapy of malignant neoplasms. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2018; 12(3): 275-282. DOI: 10.1134/S1990750818030058
• N.V. Suvorov, A.E. Machulkin, A.V. Ivanova, A.M. Popkova, E.A. Bondareva, E.A. Plotnikova, R.I. Yakubovskaya, A.G. Majouga, A.F. Mironov, M.A. Grin. Synthesis of PSMA-targeted 131- and 152-substituted chlorin e6 derivatives and their biological properties. J. Porphyrins Phthalocyanines 2018; 22: 1-9. DOI: 10.1142/S1088424618501006
• Petriev VM, Tischenko VK, Smoryzanova OA, Mikhailovskaya AA, Bolbit NM, Duflot VR, Gaivoronsky AV, Morozova NB, Yakubovskaya RI. A new radiopharmaceutical based on a thermosensitive polymer and 153Sm for local radionuclide therapy of solid tumors. Radiation and Risk (Bulletin of the National Radiation and Epidemiological Registry), 2018, vol. 27, No. 1, 66-76
• A.A. Rosenkranz, T.A. Slastnikova, T.A. Karmakova, M.S. Vorontsova, N.B. Morozova, V.M. Petriev, A.S. Abrosimov, Y.V. Khramtsov, T.N. Lupanova, A.V. Ulasov, R.I. Yakubovskaya, G.P. Georgiev, A.S. Sobolev. Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression. Frontiers in Pharmacology | . November 2018 | Volume 9 | Article 1331. 
• Morozova NB, Plotnikova EA, Plyutinskaya AD, Stramova VO, Vorontsova MS, Pankratov AA, Yakubovskaya RI, Makarova EA, Lukyanets EA, Kaprin AD. Preclinical study of the preparation “Bacteriosense” intended for photodynamic therapy of malignant neoplasms, including prostate cancer. Russian Journal of Biotherapy, 2018; 17 (3): 55-64. DOI: 10.17650/1726-9784-2018-17-3-55-64
• Bezborodova OA, Alekseenko IV, Nemtsova ER, Pankratov AA, Filyukova OB, Yakubovskaya RI, Kostina MB, Potapov VK, Sverdlov ED. Antitumor efficacy of a complex based on a binary vector system for co-expression of the suicide gene FCU1 and Cre-recombinase. Doklady Biochemistry and Biophysics, 2018; 483 (3).
• Fadeev R, Chekanov A, Solovieva M, Bezborodova O, Nemtsova E, Dolgikh N, Fadeeva I, Senotov A, Kobyakova M, Evstratova Ya, Yakubovskaya R, Akatov V. Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD. Int. J. Mol. Sci. 2019, 20, 525-535; doi:10.3390/ijms20030525
• Guryev, E.L., Shilyagina, N.Y., Kostyuk, A.B., Sencha, L.M., Balalaeva, I.V., Vodeneev, V.A., Kutova, O.M., Lyubeshkin, A.V., Yakubovskaya, R.I., Pankratov, A.A., Ingel, F.I., Novik, T.S., Deyev, S.M., Ermilov, S.A., Zvyagin, A.V. Preclinical Study of Biofunctional Polymer-Coated Upconversion Nanoparticles. (2019) Toxicological Sciences, 170 (1), pp. 123-132.
• Farrakhova, D., Maklygina, Y., Romanishkin, I., Ryabova, A., Yakavets, I., Millard, M., Bolotine, L., Plyutinskaya, A., Karmakova, T., Pankratov, A., Loschenov, V. Investigation of Ce6 accumulation and distribution in cell cultures of head and neck cancers. (2019) Progress in Biomedical Optics and Imaging — Proceedings of SPIE, 11065, article No. 110651V
• Machulkin, A.E., Skvortsov, D.A., Ivanenkov, Y.A., Ber, A.P., Kavalchuk, M.V., Aladinskaya, A.V., Uspenskaya, A.A., Shafikov, R.R., Plotnikova, E.A., Yakubovskaya, R.I., Nimenko, E.A., Zyk, N.U., Beloglazkina, E.K., Zyk, N.V., Koteliansky, V.E., Majouga, A.G. Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. (2019) Bioorganic and Medicinal Chemistry Letters, 29 (16), pp. 2229-2235.
• Ostroverkhov, P.V., Semkina, A.S., Naumenko, V.A., Plotnikova, E.A., Melnikov, P.A., Abakumova, T.O., Yakubovskaya, R.I., Mironov, A.F., Vodopyanov, S.S., Abakumov, A.M., Majouga, A.G., Grin, M.A., Chekhonin, V.P., Abakumov, M.A. Synthesis and characterization of bacteriochlorin loaded magnetic nanoparticles (MNP) for personalized MRI guided photosensitizers delivery to tumor. (2019) Journal of Colloid and Interface Science, 537, pp. 132-141.
• Sapelnikov, M.D., Nikolskaya, E.D., Morozova, N.B., Plotnikova, E.A., Efremenko, A.V., Panov, A.V., Grin, M.A., Yakubovskaya, R.I. Development of the technology for obtaining PLGA and dipropoxybacteriopurpurinimide-based nanoparticles. Evaluation of physicochemical and biological properties of the obtained delivery system. (2019) Biomedical Photonics, 8 (1), pp. 4-17.
• Plotnikova, E.A., Stramova, V.O., Morozova, N.B., Plyutinskaya, A.D., Ostroverkhov, P.V., Grin, M.A., Mironov, A.F., Yakubovskaya, R.I., Kaprin, A.D. Solubilization of hydrophobic bacteriochlorin-based photosensitizer in micelles of surfactants. (2019) Biomedical Photonics, 8 (1), pp. 18-23.
• Ostroverkhov, P., Semkina, A., Naumenko, V., Plotnikova, E., Yakubovskaya, R., Vodopyanov, S., Abakumov, A., Majouga, A., Grin, M., Chekhonin, V., Abakumov, M. HSA-coated magnetic nanoparticles for MRI-guided photodynamic cancer therapy (2018) Pharmaceutics, 10 (4), article No. 284
• Plotnikova, E.A., Grin, M.A., Ostroverkhov, P.V., Pantushenko, I.V., Yakubovskaya, R.I., Kaprin, A.D. Primary Screening of Photosensitizers of the Bacteriochlorin Series for Photodynamic Therapy of Malignant Neoplasms. (2018) Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 12 (3), pp. 275-282
• Kostryukova, L.V., Plyutinskaya, A.D., Pankratov, A.A., Korotkevich, E.I., Prozorovskiy, V.N., Tikhonova, E.G., Torkhovskaya, T.I., Teryoshkina, Y.A. Chlorin e6 in Phospholipid Nanoparticles with Specific Targeting and Penetrating Peptides as Prospective Composition for Photodynamic Therapy of Malignant Neoplasms. (2020) Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 14 (2), pp. 174-179.
• Bezborodova OA, Pankratov AA, Nemtsova ER, Venediktova YuB, Vorontsova MS, Engalycheva GN, Syubaev RD. Antitumor medicinal products: planning preclinical efficacy and safety studies. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2020. Vol. 10, No. 2, pp. 96-110
• Sapel’nikov, M.D., Nikol’skaya, E.D., Morozova, N.B., Plotnikova, E.A., Pankratov, A.A., Efremenko, A.V., Panov, A.V., Grin, M.A., Yakubovskaya, R.I. Physicochemical and Biological Properties of a Nanostructured IR-Photosensitizer Based on Dipropoxybacteriopurpurinimide (2020) Pharmaceutical Chemistry Journal, 54 (1), pp. 49-56
• Yagolovich, A.V., Artykov, A.A., Karmakova, T.A., Vorontsova, M.S., Pankratov, A.A., Andreev-Andrievsky, A.A., Dolgikh, D.A., Kirpichnikov, M.P., Gasparian, M.E. Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. (2020) Translational Oncology, 13 (4), article No. 100762
• Farrakhova, D.S., Yakovlev, D.V., Maklygina, Y.S., Ryabova, A.V., Borodkin, A.V., Loschenov, M.V., Bezdetnaya, L., Plyutinskaya, A.D., Karmakova, T.A., Pankratov, A.A., Loschenov, V.B. The research of chlorine e6 distribution and accumulation in multicellular tumor spheroid model. (2020) Optical and Quantum Electronics, 52 (2), article No. 116.
• Skobeltsin, A., Farrakhova, D., Maklygina, Y., Romanishkin, I., Ryabova, A., Yakovets, I., Millard, M., Bolotine, L., Plyutinskaya, A., Karmakova, T., Pankratov, A., Loschenov, V. 3D spheroid cultures for evaluation of nanophotosensitizers accumulation (2020) Journal of Physics: Conference Series, 1439 (1), article No. 012032
• Bezborodova, O.A., Pankratov, A.A., Nemtsova, E.R., Venediktova, Yu.B., Vorontsova, M.S., Engalycheva, G.N., Syubaev, R.D. Anti-Tumour drugs: Planning preclinical efficacy and safety studies (2020) Yakugaku Zasshi, 140 (9), pp. 1087-1094.
• ER Nemtsova, EG Tikhonova, OA Bezborodova, AA Pankratov, JB Venediktova, EI Korotkevich, LV Kostryukova, JA Tereshkina. Preclinical study of pharmacological properties of Doxorubicin-NPh. Bulletin of Experimental Biology and Medicine, 2020; 169 (6) Pharmacology and Toxicology: 778-882. DOI: 10.1007/s10517-020-04977-5
• Grin MA, Tikhonov SL, Petrova AS, Pogorilyy VA, Noev AN, Tatarskiy VV, Shpakovsky DB, Milaeva ER, Kalinina EV, Chernov NN, Shtil AA, Mironov AF, Kaprin AD, Filonenko EV. New derivatives of bacteriopurpurin with thiolated Au(I) complexes: Dual dark-and light-activated antitumor potency. Anti-Cancer Agents in Medicinal Chemistry, 2020: 20 (1); 49-58
• Torkhovskaya TI, Kostryukova LV, Tereshkina YuA, Tikhonova EG, Morozevich GE, Plutinskaya AD, Lupatov AYu, Pankratov AA. Chlorin e6 embedded in phospholipid nanoparticles equipped with specific peptides: Interaction with tumor cells with different aminopeptidase N expression. Biomedicine & Pharmacotherapy. 2021; 134: 111154. Doi.org/10.1016/j.biopha.2020.111154
• Morozova NB, Pavlova MA, Plyutinskaya AD, Pankratov AA, Efendiev KT, Semkina AS, Pritmov DA, Mironov AF, Panchenko PA, Fedorova OA. Photodiagnosis and photodynamic effects of bacteriochlorin-naphthalimide conjugates on tumor cells and mouse model. Journal of Photochemistry and Photobiology, B: Biology. 2021. Doi.org/10.1016/j.jphotobiol.2021.112294.
• Pankratov AA, Nemtsova ER, Plyutinskaya AD, Vorontsova MS, Chuvilin DYu, Egorova BV, Kokov KV, Deev SM, Lebedenko EN, Proshkina GM, Shul’ga AA, Golovachenko VA, Shegai PV, Kaprin AD. Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals. Bull Exp Biol Med 171, 627–632. 2021. doi.org/10.1007/s10517-021-05283-4.
• Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. International Journal of Molecular Sciences, 2022, 23(20), 12687.
• Chistyakov, D.V., Guryleva, M.V., Stepanova, E.S., Makarenkova LM, Ptitsyna EV, Goriainov SV, Nikolskaya AI, Astakhova AA, Klimenko AS, Bezborodova OA, Rasskazova EA, Potanina OG, Abramovich RA, Nemtsova, E.R., Sergeeva, M.G. Multi-Omics Approach Points to the Importance of Oxylipins Metabolism in Early-Stage Breast Cancer. Cancers, 2022, 14(8), 2041.
• Noev A., Kuznetsov N., Korenev G., Morozova N., Vasil’ev Yu, Suvorov N., Diachkova E., Usachev M., Pankratov A., Grin M. A Novel Photoswitchable Azobenzene-Containing Local Anesthetic Ethercaine with Light-Controlled Biological Activity In Vivo. International Journal of Molecular Sciences, 2022, 23(10), 5352.
• Farrakhova D., Maklygina Y., Romanishkin I., Yakovlev D., Plyutinskaya A., Bezdetnaya L., Loschenov V. Fluorescence Imaging Analysis of Distribution of Indocyanine Green in Molecular and Nanoform in Tumor Model. Photodiagnosis and Photodynamic Therapy 2022; 37: 102636.
• Nemtsova ER, Pankratov AA, Morozova NB, Tischenko VK, Petriev VM, Krylov VV, Shegai PV, Ivanov SA, Kaprin AD. Radioligand therapy of patients with metastatic castrate-resistant prostate cancer. Radiation Biology. Radioecology. 2022; 3: 250-263.
• Plyutinskaya AD, Nemtsova ER, Pankratov AA, Shegai PV, Krylov SS, Iskandarova VN, Maksimenko AS, Demchuk DV, Kuptsova TS, Semenova MN, Semenov VV. Cytostatic activity of combretastatin A-4 derivatives in an in vitro system. Bulletin of Experimental Biology and Medicine. 2022; 174(8): 184-189.
• Suvorov NV, Sapelnikov MD, Plotnikova EA, Morozova NB, Plyutinskaya AD, Pankratov AA, Grin MA, Filonenko EV. A new water-soluble IR photosensitizer in the bacteriochlorophyll a series. Pharmaceutical Chemistry Journal, 2022; 56(6): 10-16.
• Gracheva AV, Korchevaya ER, Samoilikov RV, Smirnova DI, Leneva IA, Pankratov AA, Trunova GV, Khokhlova VA, Nagieva FG, Svitich OA, Zverev VV, Poromov AA, Faizuloev EB. Markers of attenuation of cold-adapted SARS-CoV-2 coronavirus variants. Medical Academic Journal 2022; 1(2).
• Glazkova DV, Bogoslovskaya EV, Urusov FA, Kartashova NP, Glubokova EA, Gracheva AV, Faizuloev EB, Trunova GV, Khokhlova VA, Bezborodova OA, Pankratov AA, Leneva IA, Shipulin GA. Generation of SARS-CoV-2 Mouse Model by Transient Expression of the Human ACE2 Gene Mediated by Intranasal Administration of AAV-hACE2. Molecular Biology. 2022; 56(5): 705-712.
• Suvorov, N.V., Sapel’nikov, M.D., Plotnikova, E.A., Morozova NB, Plyutinskaya AD, Pankratov AA, Grin, M.A., Filonenko, E.V. New Water-Soluble IR Photosensitizer in the Bacteriochlorophyll a Series. Pharmaceutical Chemistry Journal 2022; 56(6): 736–741.
• Artyukhov, A.A., Golovachenko, V.A., Deev, S.M., Egorova BG, Kokov KV, Kuznetsova TM, Kurochkin AV, Lebedenko EN, Makoveeva KA, Pankratov AA, Plyutinskaya AD, Proshin MA, Chuvilin DYu, Shulga AA, Kaprin AD. Synthesis and Investigation of Radiopharmaceutical Complexes Based on 177Lu and 212Pb for the Targeted Therapy of Malignant Neoplasms. Nanobiotechnology Reports 2022; 17(3): 429–435.
• Faizuloev E, Gracheva A, Korchevaya E, Smirnova D, Samoilikov R, Pankratov A, Trunova G, Khokhlova V, Ammour Y, Petrusha O, Poromov A, Leneva I, Svitich O, Zverev V. Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. Vaccine, .
• Pogoriliy V.; Ostroverkhov P.; Efimova V.; Plotnikova E.; Bezborodova O.; Diachkova E.; Vasil’ev Y.; Pankratov A.; Grin M. Thiocarbonyl Derivatives of Natural Chlorins: Synthesis Using Lawesson’s Reagent and a Study of Their Properties. Molecules 2023, 28, 4215. doi.org/10.3390/molecules28104215.
• Zyk NY, Garanina AS, Plotnikova EA, Ber AP, Nimenko EA, Dashkova NS, Uspenskaia AA, Shafikov RR, Skvortsov DA, Petrov SA, Pankratov AA, Zyk NV, Majouga AG, Beloglazkina EK, Machulkin EA. Synthesis of Prostate-Specific Membrane Antigen-Targeted Bimodal Conjugates of Cytotoxic Agents and Antiandrogens and Their Comparative Assessment with Monoconjugates. Int. J. Mol. Sci. 2023, 24, 11327. doi.org/10.3390/ijms241411327.
• Noev A., Morozova N., Suvorov N., Vasil’ev Y., Pankratov A., Grin M. Development of a Dosage Form for a Photoswitchable Local Anesthetic Ethercaine. Pharmaceuticals 2023, 16, 1398. doi.org/10.3390/ph16101398.
• Isakova AA, Artykov AA, Plotnikova EA, Trunova GV, Khokhlova VA, Pankratov AA, Shuvalova ML, Mazur DV, Antipova NV, Shakhparonov MI, Dolgikh DA, Kirpichnikov MP, Gasparian ME, Yagolovich AV. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis. Int J Biol Macromol. 2023;255:128096. doi: 10.1016/j.ijbiomac.2023.
• Shestovskaya M.V.; Luss A.L.; Bezborodova O.A.; Makarov V.V.; Keskinov A.A. Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity. Pharmaceutics 2023, 15, 2406. doi.org/10.3390/pharmaceutics15102406.
• Ryabova A., Pominova D., Markova I., Nikitin A., Ostroverkhov P., Lasareva P., Semkina A., Plotnikova E., Morozova N., Romanishkin I., Linkov K, Abakumov M, Pankratov A, Steiner R, Loschenov V. Fluorescent Microscopy of Hot Spots Induced by Laser Heating of Iron Oxide Nanoparticles. Photonics 2023, 10, 705. doi.org/10.3390/photonics10070705.
• Grin M., Ostroverkhov P., Suvorov N., Tikhonov S., Popov A., Shelyagina A., Kirin N., Nichugovskiy A., Usachev M., Bragina N., Plotnikova E., Pankratov A. Potential agents for combined photodynamic and chemotherapy in oncology based on Pt(II) complexes and pyridine-containing natural chlorins. J. Porphyrins Phthalocyanines 2023; 27: 728–740. DOI: 10.1142/S1088424623500761.
• Leontyev DS, Glazkova DV, Bezborodova OA, Tsyganova GM, Urusov A, Pankratov AA, Shipulin GA, Bogoslovskaya EV. Humanized Mouse Model of HIV Infection. Bull Exp Biol Med. 2023;175(1):63-66. doi: 10.1007/s10517-023-05812-3.
• Minakov DA, Suvorov NV, Tikhonov SI, Plotnikova EA, Plyutinskaya AD, Grin MA. Development of Iodine-Containing Natural Chlorins as Prototypes of Radiopharmaceuticals with Iodine Radionuclides. Macroheterocycles 2023 16(2) 137-143. DOI: 10.6060/mhc235182m.
• Plotnikova EA, Morozova NB, Ryabova AV, Trunova GV, Khokhlova VA, Loschenov VB, Pankratov AA, Kaprin AD. Ascite-solid model of prostate cancer and its morphological characteristics. Siberian Journal of Oncology. 2023; 22(4): 65–73. doi: 10.21294/1814-4861-2023-22-4-65-73.
• Kolesnikov AV, Nemtsova ER, Shishkin MM, Shchul’kin AV, Barenina OI, Kirsanova IV. Lactoferrin Influence on the Course of Suppurative Corneal Ulcer. Ophthalmology in Russia 2023; 20(1): 128–135.
• Tishchenko VK, Petriev VM, Vlasova OP, Legkodimova NS, Krylov VV, Morozova NB, Pankratov AA, Shegai PV, Ivanov SA, Kaprin AD. Biodistribution of 177Lu-DOTA-PSMA in mice with prostate carcinoma 22Rv1. Pharmaceutical Chemistry Journal 2023; 57 (2): 180-185. DOI 10.1007/s11094-023-02865-6
• Isakova AA, Artykov AA, Plotnikova EA, Trunova GV, Khokhlova VA, Pankratov AA, Shuvalova ML, Mazur DV, Antipova NV, Shakhparonov MI, Dolgikh DA, Kirpichnikov MP, Gasparian ME, Yagolovich AV. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis. International Journal of Biological Macromolecules 255 (2024) 128096. doi.org/10.1016/j.ijbiomac.2023.128096
• Generalova, L.V.; Laryushkin, D.P.; Leneva, I.A.; Ivanina, A.V.; Trunova, G.V.; Dolinnyi, S.V.; Generalov, E.A. Evaluation of the Polysaccharide “Immeran” Activity in Syrian Hamsters’ Model of SARS-CoV-2. Viruses 2024; 16: 423. doi.org/10.3390/v16030423
• Shestovskaya MV, Luss AL, Bezborodova OA, Kulikov PP, Antufrieva DA, Plotnikova EA, Makarov VV, Yudin VS, Pankratov AA, Keskinov AA. Radiosensitizing effects of heparinized magnetic iron oxide nanoparticles in colon cancer. Biomedicine & Pharmacotherapy 175 (2024) 116668
• E. Plotnikova, O. Abramova, P. Ostroverkhov, A. Vinokurova, D. Medvedev, S. Tihonov, M. Usachev, A. Shelyagina, A. Efremenko, A. Feofanov, A. Pankratov, P. Shegay, M. Grin, A. Kaprin. Conjugate of Natural Bacteriochlorin with Doxorubicin for Combined Photodynamic and Chemotherapy. Int. J. Mol. Sci. 2024, 25, 7210. doi.org/10.3390/ijms25137210.
• Bezborodova OA, Pankratov AA, Kogan BY, Nemtsova ER, Venediktova JB, Karmakova TA, Butenin AV, Feizulova RK-G, Khokhlova VA, Obraztsova EA, Kaprin AD. Antitumor effect of nanophotothermolysis mediated by zinc phthalocyanine particles. Nanomedicine: Nanotechnology, Biology, and Medicine 61 (2024) 102768.
• Rakitina OA, Kuzmich AI, Bezborodova OA, Kondratieva SA, Pleshkan VV, Zinovyeva MV, Didych DA, Sass AV, Snezhkov EV, Kostina MB, Koksharov MO, Alekseenko IV. Non-viral-mediated gene transfer of OX40 ligand for tumor immunotherapy. Front. Immunol. 15:1410564. doi: 10.3389/fimmu.2024.1410564.
• Plyutinskaya AD, Nemtzova ER, Pankratov AA, Kiselyov AS, Zubarev AA, Duda KA, Kuptsova TS, Semenova MN, Semenov VV. N-Aryl-Methylimidazothiazolyl Thiazolamines: Synthesis and Evaluation for Antiproliferative Antitubulin Activity in a Sea Urchin Embryo Model and PC-3 Cancer Cells. ChemistrySelect 2024, 9, e202403700.
• Gracheva AV, Drokov AO, Smirnova DI, Khokhlova DM, Korchevaya ER, Pankratov AA, Trunova GV, Khokhlova VA, Vorontsova MS, Leneva IA, Svitich OA, Zverev VV, Faizuloev EB. Virulence and tissue tropism of different epidemiologically significant SARS-CoV-2 variants for golden Syrian hamsters. J Microbiol Epidem Immun. 2024; 101(4): 470-482. doi.org/10.36233/0372-9311-528.
• Faizuloev EB, Gracheva AV, Korchevaya ER, Ammour YuI, Smirnova DI, Khokhlova DM, Drokov AO, Pankratov AA, Trunova GV, Khokhlova VA, Vorontsova MS, Leneva IA, Svitich OA, Zverev VV. Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern. Journal of Microbiology, Epidemiology and Immunobiology. 2024; 101(1): 36–51. doi.org/10.36233/0372-9311-496.
• Nemtsova ER, Morozova NB, Plyutinskaya AD, Noev AN, Pankratov AA, Shegai PV. Combretastatins A-4 and A-1 and their derivatives: a review. Russian Journal of Biotherapy 2024; 23(1): 10-18.
• Kolesnikov AV, Nemtsova ER, Cherdantseva TM, Kirsanova IV, Kislyakova TD. Effect of human lactoferrin solution on histological changes of the rabbit cornea in alkaline burns. Kazan Medical Journal. – 2024. – Vol. 105, No. 1. – P. 90-98. – DOI 10.17816/KMJ115265.
• Noev AN, Kovalenko SG, Gataulina ED, Turchaninova EA, Dzhabrailov VD, Aitova AA, Likhobabina DA, Sutemieva ZhA, Frolova ShR, Ruppel LE, Minakov DA, Suvorov NV, Ostroverkhov PV, Vasiliev YuL, Nikolaev MV, Tsvelaya VA, Agladze KI, Grin MA. Azobenzene-based blockers of voltage-gated sodium channels with light-controlled local anesthetic and antiarrhythmic activity. Biophysics (BIOPHYSIKA), 2024, vol. 69, No. 3, pp. 574–593. doi:10.31857/S0006302924030144.
• Nemtsova ER, Morozova NB, Plyutinskaya AD, Noev AN, Pankratov AA, Demchuk DV, Krylov SS, Semenov VV, Shegay PV, Kaprin AD. Diaryl isoxazole analog of combretastatin A4 (a promising substance for antitumor drugs). Pharmaceutical Chemistry Journal 2025; 58(10): 1469-1474. DOI 10.1007/s11094-025-03297-0.
• Shestovskaya MV, Luss AL, Bezborodova OA, Venediktova YB, Vorontsova MS, Vlaskina ER, Kushnerev KS, Makarov VV, Yudin VS, Keskinov AA. Iron oxide nanoparticles as enhancers for radiotherapy of tumors. ACS Applied Bio Mater. 2025; 8(3): 2535-2547
• Bezborodova OA, Trunova GV, Nemtsova ER, Khokhlova VA, Venediktova JB, Morozova NB, Vorontsova MS, Plyutinskaya AD, Zharova EP, Shegai PV, Kaprin AD. Targets for CAR Therapy in Multiple Myeloma. Int. J. Mol. Sci. 2025, 26, 6051. doi.org/10.3390/ijms26136051
• Noev, A.; Likhobabina, D.; Sutemieva, J.; Plyutinskaya, A.; Cheshkov, D.; Morozova, N.; Vinokurova, A.; Vasil’ev, Y.; Suvorov, N.; Nemtzova, E.; Pankratov, A.; Filonenko, E.; Shegay, P.; Kaprin, A.; Grin, M. Structure–Property Relationships in Novel Series of Photoswitchable Local Anesthetic Ethercaine Derivatives: Emphasis on Biological and Photophysical Properties. Int. J. Mol. Sci. 2025, 26, 3244. Doi.org/10.3390/ijms26073244
• Nemtsova ER, Plotnikova EA. Modern Approaches to Enterovirus-Based Oncolytic Immune Virotherapy of Malignant Diseases. Pharmacy & Pharmacology. 2025;13(2): 111-127. DOI: 10.19163/2307-9266-2025-13-2-111-127
• Kiselev, V.; Leneva, I.; Ivanina, A.; Poromov, A.; Falynskova, I.; Kartashova, N.; Glubokova, E.; Trunova, G.; Sudakov, S.; Drukh, V.; Zverev V; Kiselev O. 3,3′-Diindolylmethane Improves the Viral Pneumonia Outcomes After Influenza and SARS-CoV-2 Infection in Animal Models. Viruses 2025; 17: 964. 
• Shein DA, Ryzhova NN, Kunda MS, Ermolova EI, Ozharovskaya TA, Popova O., Nikitenko NA, Krasnoslobodtsev KG, Burtseva EI, Zubkova OV, Voronina OL, Gintsburg AL. Genetic characterization of a human adenovirus genotype 55 isolate (Adenoviridae: Mastadenovirus) first isolated in Moscow. Problems of Virology. 2025. doi.org/10.36233/0507-4088-297.
• Voronina, D.V.; Vavilova, I.V.; Zubkova, O.V.; Ozharovskaia, T.A.; Popova, O.; Chugunova, A.S.; Goldovskaya, P.P.; Zrelkin, D.I.; Savina, D.M.; Favorskaya, I.A.; et al. Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice. Viruses 2025, 17, 1085. doi.org/10.3390/v17081085.
• Shcheblyakov DV, Favorskaya IA, Dolzhikova IV, Korobkova AI, Alekseeva IA, Esmagambetov IB, Voronina OL, Tukhvatulin AI, Zubkova OV, Derkaev AA, Ryabova EI, Iliukhina AA, Zorkov ID, Grousova DM, Reshetnikov DA, Ryzhova NN, Ermolova EI, Kunda MS, Matyuta IO, Boyko KM, Popov VO, Logunov DY, Sluchanko NN, Gintsburg AL. Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity. International Journal of Biological Macromolecules, 2025; 319 (Part 3): 145386. doi: 10.1016/j.ijbiomac.2025.145386
• Druzhkova IN, Orlova AG, Fedulova AS, Avakiants AV, Isakova AA, Kukovyakina EV, Zijian Y, Plotnikova EA, Trunova GV, Pankratov AA, Plekhanov AA, Kurnikov AA, Subochev PV, Shaytan AK, Gasparian ME, Kirpichnikov MP, Dolgikh DA, Razansky D, Yagolovich AV. Multivalent fusion protein targeting VEGFR2 and DR5 receptors: assessing the antiangiogenic and antitumor effects via multimodal microangiography. Journal of Translational Medicine (2025) 23:949. doi.org/10.1186/s12967-025-06859-8.
• Minakov DA, Egorov AE, Noev AN, Ostroverkhov PV, Suvorov NV, Usachev MN, Cheshkov DA, Kostyukov AA, Nekipelova TD, Zevakin EA, Kuzmin VA, Filonenko EV, Grin MA. Synthesis and photophysical properties of a chlorin conjugate with a photoswitchable local anesthetic. Journal of Photochemistry & Photobiology, B: Biology, 2025. Vol. 271, 113238. DOI: 10.1016/j.jphotobiol.2025.113238
• Ozharovskaia, T.A.; Zubkova, O.V.; Korobova, E.V.; Dolzhikova, I.V.; Zrelkin, D.I.; Popova, O.; Goldovskaya, P.P.; Kovyrshina, A.V.; Korobkova, A.I.; Favorskaya, I.A. Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge. Vaccines 2025, 13, 1177. doi.org/10.3390/vaccines13121177.
• Davydov DV, Karpechkin MO, Morozova NB, Khokhlova VA, Perova NV, Nemechkina AO. Effect of a heterogeneous collagen-containing composition on the growth and metastasis of B16-F1y mouse melanoma: an experimental cohort-controlled study. Ophthalmic Reports 2025, 18(4); 35-42. Doi: 10.17816/OV693958
• Ostroverkhov PV, Plyutinskaya AD, Luneva KV, Borzhitskaya EO, Lavrinova PE, Govorov ND, Golovanov AB, Neryabova ES, Martinov LY, Usachev MN, Filonenko EV, Bezborodova OA, Grin MA. Synthesis and evaluation of the combined chemotherapeutic and photodynamic action of new Pt-complexes of natural chlorins. Journal of Inorganic Biochemistry 2026; 227: 113240. 
• Cherepenin VA, Vdovin VA, Morozova NB, Plyutinskaya AD, Sapetsky SA, Denisov RA. Nonthermal exposure of oncological objects to high-power electromagnetic pulses in vitro and in vivo. Doklady Physics. 2026. Vol. 528. Pp. 50–57. 
• Nemtsova ER, Bezborodova OA, Trunova GV, Morozova NB, Plyutinskaya AD, Vorontsova MS, Venediktova YuB, Khokhlova VA, Goshina DM, Kan VYu, Zharova EP, Shegai PV, Kaprin AD. PLGA nanoparticles as a delivery vehicle for antitumor agents. P.A. Herzen Journal of Oncology 2026, Vol. 15, No. 4, pp. 116–123. 
• Semochkin SV, Chervontseva AM, Vernyuk MA, Lunin VV, Tarasenkova AA, Akhmedov MI, Cherkashina IV, Khairullina LS, Nemtsova ER, Venediktova YuB, Fedenko AA, Kaprin AD. Immediate and long-term results of autologous hematopoietic stem cell transplantation: the experience of the P.A. Herzen MNIOI (2020-2025). Oncohematology 2026; 21 (2): 92-104. 
• Savelyeva I, Govorov N, Gradova M, Gruznova O, Karpechenko N, Chesnokova I, Gruznov D, Popov N, Shcherbakova G, Shuteeva E, Kuvshinchikov N, Tyumentseva V, Aybush A, Syrchina M, Pchelkina V, Markova A, Smolyaninova L, Pervushin N, Bezborodova O, Bragina N, Zhdanova K. A Detailed Study of the Antimicrobial and Antitumor Activity of ABAB-and A4-Type Cationic Porphyrins in Free or Polymeric Forms. J Med Chem. 2026;69(15):19502-19524. doi: 10.1021/acs.jmedchem.6c01974
• Zhdanova K., Savelyeva I, Markova A, Nguyen M.T., Egorov A.E., Voitova A.V., Rybkin A.Yu., Filatova N.V., Bondarenko S.D., Mishchenko DV, Gradova M.A., Karpechenko N.Yu., Maksimova V.P., Popova V.G., Govorov N.D., Bezborodova O.A., Kuzmin V.A., Bragina N.A. Novel π-extended cationic meso-arylporphyrins as photosensitizers for photodynamic therapy: Synthesis, photoinduced toxicity and in vivo fluorescence. J Photochem Photobiol B. 2026; 281:113497. doi: 10.1016/j.jphotobiol.2026.113497

• Patent for Invention No. 2548726, registered 20.04.2015. Photosensitizer for photodynamic therapy. Yakubovskaya RI, Solovyeva LI, Koifman OI, Ponomarev GV, Lastovoy AP, Lukyanets EA, Morozova NB, Plotnikova EA.
• Patent No. 2548675 dated 13.01.2015. Aminoamides in the bacteriochlorophyll a series possessing photodynamic activity, and a method for their production. Mironov AF, Reshetnikov RI, Grin MA, Yakubovskaya RI, Plotnikova EA, Morozova NB, Tsigankov AA, Feofanov AV, Ermakova DE, Efremenko AV.
• Patent of the Russian Federation No. 2551784, registered April 23, 2015. Universal promoter for the expression of therapeutic genes in mammalian cells. Sverdlov ED, Alekseenko IV, Bezborodova OA, Vinogradova TV, Kashkin KN, Kopantzev EP, Monastyrskaya GS, Nemtsova ER, Uspenskaya NYa, Chernov IP, Yakubovskaya RI.
• Patent No. 2571551, registered November 24, 2015, published December 20, 2015. Specific combined therapy of malignant tumors with a cytostatic drug and its modifier. Andronova TM, Yakubovskaya RI, Nemtsova ER, Nesterova EI.
• Patent No. 2575077, registered 10.02.2016. Pharmaceutical combination of the polycationic carrier PEG-PEI-TAT with a plasmid incorporated therein carrying the therapeutic genes HSVtk and GM-CSF for the purposes of gene therapy of tumor diseases. Alekseenko IV, Vinogradova TV, Zinovyeva MV, Kopantzev EP, Monastyrskaya GS, Kostina MB, Snezhkov EV, Chernov IP, Pleshkan VV, Kostrov SV, Potapov VK, Bezborodova OA, Nemtsova ER, Yakubovskaya RI, Uspenskaya NYa, Rosenkranz AA, Sobolev AS, Ulasov AV, Khramtsov YuB, Sverdlov ED.
• Patent No. 2602362 dated 20.11.2016. Method for the treatment of purulent corneal ulcer. Kolesnikov AV, Shchulkin AV, Barenina OI, Yakubovskaya RI, Nemtsova ER, Pankratov AA, Shmarov MM, Ataullakhanov RR.
• Patent No. 2613106 C2, published 15.03.2017, Bulletin No. 8. Method for producing a medicinal product, and a medicinal product. Khromov AV, Feizulova RK-G, Kogan BYa, Yakubovskaya RI, Pankratov AA.
• Patent for Invention No. 2663900, dated 13.08.2018, Bulletin No. 23. Water-soluble dosage form of meso-tetra(3-pyridyl)bacteriochlorin for photodynamic therapy. Lukyanets EA, Makarova EA, Kalinichenko AN, Starkova NN, Bezulenko VN, Kobzeva ES, Yakubovskaya RI, Morozova NB, Plotnikova EA, Plyutinskaya AD, Stramova VO.
• Eurasian Patent No. 031099 dated 30.11.2018. Specific combined therapy of malignant tumors with a cytostatic drug and its modifier. Andronova TM, Yakubovskaya RI, Nemtsova ER, Nesterova EI.
• Patent No. 2682039 dated 14.03.2019. Peptide possessing antitumor and antimetastatic activity, and a finished dosage form based thereon. Bogachuk AP, Zolotarev YuA, Azev IN, Surina EA, Smirnova E, Smirnova IV, Yakubovskaya RI, Nemtsova ER, Morozova NB, Vorontsova MS, Lipkin VM.
• Patent No. 2687092 dated 05.04.2019. Pharmaceutical composition for intraoperative visualization of lymph nodes by indirect color lymphography. Kaprin AD, Yakubovskaya RI, Pankratov AA, Nyushko KM, Iskandarov AA, Krylov SS, Blinnikov AN.
• Patent No. 2714137, registered 12.02.2020. Phospholipid composition of doxorubicin for the treatment of patients with breast cancer. Ipatova OM, Tikhonova EG, Sanzhakov MA, Tereshkina YuA, Kostryukova LV, Korotkevich EI, Nemtsova ER, Pankratov AA, Bezborodova OA.
• Patent No. 2727059 dated 17.03.2020. Method for suppressing tumor growth with a genetically modified variant of the cytokine TRAIL. Gasparian ME, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Artykov AA, Karmakova TA, Vorontsova MS.
• Patent No. 2720806, published 13.05.2020, Bulletin No. 14. Bacteriochlorin-series photosensitizer for photodynamic therapy and a method for its production. Grin MA, Filonenko EV, Mironov AF, Suvorov NV, Pankratov AA, Grigoryevykh NI.
• Patent No. 2766298, registered March 14, 2022. Method for the treatment of corneal burns. Pankratov AA, Nemtsova ER, Kolesnikov AV, Kirsanova IV, Shchulkin AV.
• Patent No. 2782930, registered November 7, 2022. Method for isolating lymphotropin from the industrial dye “disulfine blue.” Kaprin AD, Shegai PV, Pankratov AA, Venediktova YuB, Blinnikov AN, Nikitin SV, Semenov VV, Semenova MN, Iskandarov VN, Krylov SS, Sakharov AM.
• Patent No. 2799312. Method for producing 4,5-diarylazoles. Registered 04.07.2023. Kaprin AD, Shegai PV, Nemtsova ER, Plyutinskaya AD, Morozova NB, Trunova GV, Vorontsova MS, Blinnikov AN, Semenov VV, Semenova MN, Iskandarov VN, Krylov SS, Sakharov AM, Demchuk DV.
• Patent No. 2023108842, published 27.03.2024. Methods of combined therapy of malignant neoplasms using iron oxide nanoparticles. S.M. Yudin, A.A. Keskinov, V.V. Makarov, Kulikov PP, Luss AL, Pankratov AA, Trunova GV, Bezborodova OA, Plotnikova EA.
• Patent of the Russian Federation No. 2836222 C1, published 11.03.2025, Bulletin No. 8. Optimized poliovirus type 3 strain for the therapy of solid tumors. Lipatova AV, Vorobyev PO, Kuprash DV, Kochetkov DV, Chumakov PM, Makarov AA, Kaprin AD, Shegai PV, Bezborodova OA, Pankratov AA, Plotnikova EA, Rerberg AG.